Kaposi's sarcoma-associated herpesvirus: The role of lytic replication in targeted therapy

Current Opinion in Infectious Diseases

Volumn 28, Issue 6, 2015, Pages 611-624

  Andrei, Graciela ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

antivirals; human herpesvirus 8; Kaposi sarcoma; Kaposi's sarcoma associated herpesvirus; lytic induction therapy; molecular targeted therapy

Indexed keywords

ACICLOVIR; ANTIHERPESVIRUS DRUG; ANTIVIRUS AGENT; BORTEZOMIB; CIDOFOVIR; DNA TOPOISOMERASE INHIBITOR; FOSCARNET; GANCICLOVIR; HISTONE DEACETYLASE INHIBITOR; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL THERAPY; GENE ACTIVATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; REVIEW; VIRAL LYTIC INDUCTION THERAPY; VIRUS CARCINOGENESIS; VIRUS LATENCY; VIRUS REPLICATION; DRUG EFFECTS; HERPESVIRIDAE INFECTIONS; HUMAN; PATHOLOGY; PHYSIOLOGY; SARCOMA, KAPOSI; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; SARCOMA, KAPOSI; TREATMENT OUTCOME; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84946753859     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000213     Document Type: Review

References (124)

1. Gessain A, Duprez R. Spindle cells and their role in Kaposi's sarcoma. Int J Biochem Cell Biol 2005; 37:2457-2465.
2. Ablashi DV, Chatlynne LG, Whitman JE Jr, Cesarman. Ablashi DV. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 2002; 15:439-464.
3. Dourmishev LA, Dourmishev AL, Palmeri D, et al. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 2003; 67:175-212.
4. Longnecker R, Neipel R. Introduction to the human gammaherpesviruses. In: Arwin A, Campadelli F, Mocarski E, editors. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press; 2007. pp. 341-359.
5. Ganem D. KSHV-induced oncogenesis. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press. 2007. pp. 1007-1028.
6. Martin JN. The epidemiology of KSHV and its association with malignant disease. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press; 2007. pp. 960-985.
7. Sullivan RJ, Pantanowitz L, Caspe C, et al. Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008; 47:1209-1215.
8. Laurent C, Meggetto F, Brousset P. Human herpesvirus 8 infections in patients with immunodeficiencies. Hum Pathol 2008; 39:983-993.
9. Chakraborty S, Veettil MV, Chandran B. Kaposi's sarcoma associated herpesvirus entry into target cells. Front Microbiol 2012; 3:6. doi: 10. 3389/fmicb. 2012. 00006.
10. Purushothaman P, Uppal T, Verma SC. Molecular biology of KSHV lytic reactivation. Viruses 2015; 7:116-153.
11. Boss IW, Plaisance KB, Renne R. Role of virus-encoded microRNAs in herpesvirus biology. Trends Microbiol 2009; 17:544-553.
12. Bellare P, Ganem D. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: An evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 2009; 6:570-575.
13. Chugh PE, Sin SH, Ozgur S, et al. Systemically circulating viral and tumorderived microRNAs in KSHV-associated malignancies. PLoS Pathog 2013; 9:e1003484. doi: 10. 1371/journal. ppat. 1003484.
14. Ramalingam D, Kieffer-Kwon P, Ziegelbauer JM. Emerging themes from EBV and KSHV microRNA targets. Viruses 2012; 4:1687-1710.
15. Avey D, Brewers B, Zhu F. Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis. Virol Sin 2015; 30:130-145.
16. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol 2014; 9:349-372.
17. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120:939-949.
18. Ruocco E, Ruocco V, Tornesello ML, et al. Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol 2013; 31:413-422.
19. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett 2011; 305:150-162.
20. Fatahzadeh M. Kaposi sarcoma: review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113:2-16.
21. Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 2011; 62:157-170.
22. Rohner E, Valeri F, Maskew M, et al. Incidence rate of Kaposi sarcoma in HIVinfected patients on antiretroviral therapy in Southern Africa: A prospective multicohort study. J Acquir Immune Defic Syndr 2014; 67:547-554.
23. Maskew M, Fox MP, van Cutsem G, et al. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: A cohort study. PLoS One 2013; 8:e64392. doi: 10. 1371/journal.-pone. 0064392.
24. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-5228.
25. Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS 2013; 27:1603-1613.
26. Achenbach CJ, Harrington RD, Dhanireddy S, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424-433.
27. Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10:1101-1105.
28. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173:1477-1480.
29. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose aciclovir in patients with human immunodeficiency virus infection: A metaanalysis of randomized individual patient data. J Infect Dis 1998; 178:349-359.
30. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Eng J Med 1999; 340:1063-1070.
31. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23-30.
32. Simonart T, Noel JC, De Dobbeleer G, et al. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. J Med Virol 1998; 55:215-218.
33. Hammoud Z, Parenti DM, Simon GL. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin Infect Dis 1998; 26: 1233.
34. Badiaga S, Parola P, Zandotti C, Brouqui P. Successful treatment of Kaposi's sarcoma with a combination of antiviral drug therapy and chemotherapy: Two case reports. Clin Infect Dis 1998; 27:1558-1559.
35. Fife K, Gill J, Bourboulia D, et al. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Br J Dermatol 1999; 141:1148-1149.
36. Mazzi R, Parisi SG, Sarmati L, et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 2001; 15:2061-2062.
37. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 2003; 187:149-153.
38. Verucchi G, Calza L, Trevisani F, et al. Human herpesvirus-8-related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. Transpl Infect Dis 2005; 7:34-37.
39. Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis 2011; 203:1082-1086.
40. Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 2000; 111: 1112-1115.
41. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15:280-282.
42. Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005; 19:473-476.
43. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A nonchemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006; 17:1849-1850.
44. Stingaciu S, Ticchioni M, Sudaka I, et al. Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient. Clin Adv Hematol Oncol 2010; 8:367-374.
45. Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS 2006; 20:1567-1569.
46. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368-4369.
47. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIVassociated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-1634.
48. Valencia ME, Moreno V, Martinez P, Casado I. Favorable outcome of Castleman's disease treated with oral valganciclovir. Med Clin (Barc) 2005; 125:399.
49. Senanayake S, Kelly J, Lloyd A, et al. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003; 71:399-403.
50. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: A pilot study of virus-activated cytotoxic therapy. Blood 2011; 117:6977-6986.
51. Hosseinipour MC, Sweet KM, Xiong J, et al. Viral profiling identifies multiple subtypes of Kaposi's sarcoma. mBio 2014; 5:e01633-14. doi: 10. 1128/ mBio. 01633-14.
52. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol 2003; 21:3948-3954.
53. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol 2011; 29:2481-2486.
54. Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman's disease. Am J Hematol 2008; 83:498-503.
55. McCall J, Phillips JC. Multicentric Castleman's disease: An emerging opportunistic infection. J Assoc Nurses AIDS Care 2013; 24:88-90.
56. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19:3659-3670.
57. Reddy D, Mitsuyasu R. HIV-associated multicentric Castleman disease. Curr Opin Oncol 2011; 23:475-481.
58. Rokx C, Rijnders BJ, van Laar JA. Treatment of multicentric Castleman's disease in HIV-1 infected and uninfected patients: A systematic review. Neth J Med 2015; 73:202-210.
59. Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: The roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011; 24:295-301.
60. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113:124-136.
61. Staskus KA, Zhong W, Gebhard K, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997; 71:715-719.
62. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156:743-749.
63. Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269: 335-344.
64. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069-2073.
65. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008; 18:321-329.
66. Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010; 289:140-150.
67. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151:1517-1522.
68. Pegtel DM. Oncogenic herpesviruses sending mixed signals. Proc Natl Acad Sci U S A 2013; 110:12503-12504.
69. Meckes DG Jr, Shair KH, Marquitz AR, et al. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A 2010; 107:20370-20375.
70. Meckes DG Jr, Gunawardena HP, Dekroon RM, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A 2013; 110:E2925-E2933.
71. Pellet C, Chevret S, France. , et al.s C, et al. Prognostic value of quantitative Kaposi sarcoma: Associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002; 186:110-113.
72. Pellet C, Chevret S, Blum L, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117:858-863.
73. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109-2116.
74. Pellet C, Kerob D, Dupuy A, et al. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol 2006; 126:621-627.
75. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346:799-802.
76. Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847-1851.
77. Humphrey RW, O'Brien TR, Newcomb FM, et al. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: Association with KS and persistence in patients receiving antiherpesvirus drugs. Blood 1996; 88:297-301.
78. Coen N, Duraffour S, Snoeck R, AndreiG. KSHV targeted therapy: An update on inhibitors of viral lytic replication. Viruses 2014; 6:4731-4759.
79. Coen N, Singh U, Vuyyuru V, et al. Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses. J Virol 2013; 87:3839-3851.
80. Coen N, Duraffour S, Haraguchi K, et al. Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases. Antimicrob Agents Chemother 2014; 58:4328-4340.
81. Coen N, Duraffour S, Naesens L, et al. Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells. J Virol 2013; 87:12422-12432.
82. Lin K, Ricciardi RP. A rapid plate assay for the screening of inhibitors against herpesvirus DNA polymerases and processivity factors. J Virol Methods 2000; 88:219-225.
83. Dorjsuren D, Burnette A, Gray GN, et al. Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis. Antiviral Res 2006; 69:9-23.
84. Zhang YJ, Wang KY, Stein DA, et al. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus by morpholino oligomers. Antiviral Res 2007; 73:12-23.
85. Caselli E, Galvan M, Santoni F, et al. Retinoic acid analogues inhibit human herpesvirus 8 replication. Antivir Ther 2008; 13:199-209.
86. Tong L. Viral proteases. Chem Rev 2002; 102:4609-4626.
87. Borthwick AD, Davies DE, Ertl PF, et al. Design and synthesis of pyrrolidine-5, 5'-trans-lactams (5-oxo-hexahydropyrrolo[3, 2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. J Med Chem 2003; 46:4428-4449.
88. Gopalsamy A, Lim K, Ellingboe JW, et al. Design and syntheses of 1, 6-naphthalene derivatives as selective HCMV protease inhibitors. J Med Chem 2004; 47:1893-1899.
89. Batra R, Khayat R, Tong L. Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease. Nat Struct Biol 2001; 8:810-817.
90. Khayat R, Batra R, Qian C, et al. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease. Biochemistry 2003; 42:885-891.
91. Reiling KK, Pray TR, Craik CS, Stroud RM. Functional consequences of the Kaposi's sarcoma-associated herpesvirus protease structure: regulation of activity and dimerization by conserved structural elements. Biochemistry 2000; 39:12796-12803.
92. Shahian T, Lee GM, Lazic A, et al. Inhibition of a viral enzyme by a smallmolecule dimer disruptor. Nat Chem Biol 2009; 5:640-646.
93. Lee GM, Shahian T, Baharuddin A, et al. Enzyme inhibition by allosteric capture of an inactive conformation. J Mol Biol 2011; 411:999-1016.
94. Gable JE, Lee GM, Jaishankar P, et al. Broad-spectrum allosteric inhibition of herpesvirus proteases. Biochemistry 2014; 53:4648-4660.
95. Cho HJ, Jeong SG, Park JE, et al. Antiviral activity of angelicin against gammaherpesviruses. Antiviral Res 2013; 100:75-83.
96. Gould F, Harrison SM, Hewitt EW, Whitehouse A. Kaposi's sarcomaassociated herpesvirus RTA promotes degradation of the Hey1 repressor protein through the ubiquitin proteasome pathway. J Virol 2009; 83:6727-6738.
97. Sullivan RJ, Pantanowitz L, Dezube BJ. Targeted therapy for Kaposi sarcoma. BioDrugs 2009; 23:69-75.
98. Dezube BJ, Sullivan R, Koon HB. Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science. J Cell Physiol 2006; 209:659-662.
99. Mesri EA, Cavallin LE, Ashlock BM, et al. Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis. Immunol Res 2013; 57:159-165.
100. Ashlock BM, Ma Q, Issac B, Mesri EA. Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication. PLoS One 2014; 9:e87324. doi: 10. 1371/journal. pone. 0087324.
101. Koon HB, Krown SE, Lee JY, et al. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 2014; 32:402-408.
102. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23:982-989.
103. Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24:1389-1394.
104. Qin Z, Dai L, Trillo-Tinoco J, et al. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther 2014; 13:154-164.
105. Hahn AS, Kaufmann JK, Wies E, et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus. Nat Med 2012; 18:961-966.
106. Chakraborty S, Veettil MV, Bottero V, Chandran B. Kaposi's sarcomaassociated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc Natl Acad Sci U S A 2012; 109:E1163-E1172.
107. Li R, Hayward SD. Potential of protein kinase inhibitors for treating herpesvirus-associated disease. Trends Microbiol 2013; 21:286-295.
108. Chen J, Jiang L, Lan K, Chen X. Celecoxib inhibits the lytic activation of kaposi's sarcoma-associated herpesvirus through down-regulation of RTA expression by inhibiting the activation of p38 MAPK. Viruses 2015; 7:2268-2287
109. Cheng F, Sawant TV, Lan K, et al. Screening of human kinome identifies MSK1/2-CREB1 as an essential pathway mediating KSHV lytic replication during primary infection. J Virol 2015; 89:9262-9280.
110. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: An expanding army attacking a unique target. Chem Biol 2012; 19:99-115.
111. Hughes DJ, Wood JJ, Jackson BR, et al. NEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog 2015; 11:e1004771. doi: 10. 1371/ journal. ppat. 1004771.
112. Gutierrez-Dalmau A, Sánchez-Fructuoso A, Sanz-Guajardo A, et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 2005; 37:3836-3838.
113. Geissler EK. The impact of mTOR inhibitors on the development of malignancy. Transplant Proc 2008; 40:S32-S35.
114. Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/ HHV8: insights into the antitumor activity of an immunosuppressant drug. PloS one 2011; 6:e14535. doi: 10. 1371/journal. pone. 0014535.
115. Barozzi P, Riva G, Vallerini D, et al. Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients. Transplantation 2009; 88:597-598.
116. Gonzá lez-Molleda L, Wang Y, Yuan Y. Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother 2012; 56:893-902.
117. Wang Y, Li H, Tang Q, et al. Kaposi's sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: involvement of host cellular factors. J Virol 2008; 82:2867-2882.
118. Xu B, Wang L, Gonzalez-Molleda L, et al. Antiviral activity of ()-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II. Antimicrob Agents Chemother 2014; 58:563-573.
119. Lechowicz M, Dittmer DP, Lee JY, et al. Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis 2009; 49:1946-1949.
120. Brown HJ, McBride WH, Zack JA, Sun R. Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther 2005; 10:745-751.
121. Reid EG. Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies. Curr Opin Oncol 2011; 23:482-487.
122. Li Q, He M, Zhou F, et al. Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle. J Virol 2014; 88:6355-6367.
123. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005; 105:4028-4034.
124. Kang H, Song J, Choi K, et al. Efficient lytic induction of Kaposi's sarcomaassociated herpesvirus (KSHV) by the anthracyclines. Oncotarget 2014; 5:8515-8527.